Prepared by Ada Cockpit | v4 Format | March 2026
| Drug | Indication | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity (USA, 5%) |
|---|---|---|---|---|---|
| Elfabrio | Fabry disease | TIER 1 | 8.5/10 | 6,000–14,000 | $6.8M–$15.8M/yr |
| Lamzede | Alpha-mannosidosis | TIER 2 | 7.0/10 | 105–240 | $0.6M–$1.5M/yr |
| Filsuvez | Epidermolysis bullosa | TIER 2 | 6.5/10 | 500–1,500 | $0.3M–$1.9M/yr |
| Seralutinib | PAH (Trial Finder) | TIER 2 | 6.0/10 | 5,000–10,000 (undiagnosed PAH) | ~$2M (200 enrollees) |
| Raxone | LHON | TIER 3 | 5.5/10 | N/A (EU only) | $0.04M–$0.09M/yr (DACH) |
| Arbor (ABO-101) | PH1 (Trial Finder) | TIER 3 | 5.0/10 | 100–500 | Too early |
| Ferriprox | Iron overload | TIER 3 | 4.0/10 | 600–1,200 | $0.13M–$0.35M/yr |
| Trimbow | COPD/Asthma | NO | 2.0/10 | N/A (millions) | N/A |
| Fostair/Foster | Asthma/COPD | NO | 1.5/10 | N/A (millions) | N/A |
Fabry disease has a 10–15 year diagnostic delay, ~80% of patients undiagnosed, $225K/year per patient value, and Ada's symptom checker can realistically surface the condition. Chiesi is a new entrant fighting Sanofi's decades-old Fabrazyme monopoly and lost EU orphan exclusivity — they need patient finding.
Ada revenue per patient found: $18,000–$27,000
Key contact: Giacomo Chiesi (EVP Global Rare Diseases, family member)
| Market | Total Prevalence | Diagnosed | Undiagnosed | Drug-Addressable Undiagnosed |
|---|---|---|---|---|
| USA | 30,000–50,000 | ~9,200 | 20,800–40,800 | 6,000–14,000 |
| DACH | 5,000–12,000 | ~2,500 | 2,500–9,500 | 1,500–5,000 |
| ROW | 15,000–30,000 | ~6,800 | 8,200–23,200 | 4,000–12,000 |
| Metric | Value |
|---|---|
| WAC (est.) | ~$300,000/year (Fabrazyme benchmark) |
| Net revenue/patient | ~$225,000/year (25% G2N) |
| Global Fabry market (2024) | ~$1.7B (7MM) / ~$2.7B (global) |
| Peak revenue (Elfabrio) | $500M–$1B |
| US exclusivity | Biologics 12-year (~2035); patent restoration pending |
| EU exclusivity | 8+2 data exclusivity (orphan withdrawn) |
| Top competitors | Fabrazyme (Sanofi, 40–50%), Replagal (Takeda, EU), Galafold (Amicus, oral) |
| Symptoms | Burning extremity pain (acroparesthesias), GI symptoms, heat intolerance, angiokeratomas, cornea verticillata, progressive kidney/cardiac disease |
| Diagnostic delay | 10–15 years (median 14yr adults, 10.5yr recent). Sources: PubMed 28097762 |
| Common misdiagnoses | Rheumatologic conditions, IBS, fibromyalgia, growing pains, MS, "psychosomatic" |
| Ada can identify? | YES (8/10) — Classic symptom pattern is distinctive and assessable |
| Treatment | Lifelong biweekly IV infusions. First-line ERT. |
Critical context: Elfabrio lost EU orphan exclusivity at approval. Chiesi's rare diseases segment grew 41% CER in 2024. Giacomo Chiesi (family member) personally leads this franchise. Chiesi ran a survey explicitly about Fabry diagnostic gaps. They are actively seeking ways to find patients.
| Scenario | USA | DACH | ROW |
|---|---|---|---|
| PF finds 1% of addressable | $1.4M–$3.2M/yr | $0.2M–$0.8M/yr | $0.6M–$1.8M/yr |
| PF finds 5% of addressable | $6.8M–$15.8M/yr | $1.2M–$4.1M/yr | $3.0M–$9.0M/yr |
Limitation: EB is typically diagnosed at birth from visible skin fragility. Ada's symptom checker adds limited diagnostic value. Opportunity is in patient navigation — connecting known EB patients with milder DEB to approved therapies they may not know about.
| Market | DEB+JEB Prevalence | Drug-Addressable Undiagnosed |
|---|---|---|
| USA | ~8,750–31,500 | 500–1,500 |
| DACH | ~500–1,500 | 80–250 |
| ROW | ~16,000–25,000 | 1,500–2,500 |
Competition: Vyjuvek (gene therapy, $1.26M/yr) and Zevaskyn ($3.1M one-time) are capturing DEB market aggressively.
Highest per-patient value in portfolio. Lamzede is the ONLY approved treatment. ~$1.46M WAC/year for a 70kg patient. Every patient found generates $117K+ in Ada fees. But patient pool is tiny (~105–240 addressable in US) and Ada's ability to surface the condition is moderate.
| Market | Estimated Prevalence | Diagnosed | Drug-Addressable Undiagnosed |
|---|---|---|---|
| USA | 335–670 | ~50–100 | 105–240 |
| DACH | 100–200 | ~30–60 | 50–100 |
| ROW | 500–1,000 | ~100–200 | 170–400 |
Poor fit. Iron overload patients are already in the healthcare system (being transfused). Generic competition erodes branded value. Not a strategic priority for Chiesi. Only viable in ROW markets with thalassemia underdiagnosis.
| Market | Diagnosed PAH | Undiagnosed PAH |
|---|---|---|
| USA | 5,000–6,700 | 5,000–10,000 |
| DACH | 2,500–3,500 | 2,500–5,000 |
Too early. Phase 1/2 dose-escalation trial at Mayo Clinic. PH1 hides behind recurrent kidney stones (diagnostic delay exists), but patient pool is tiny and trial needs are small at this stage. Revisit at Phase 3 (~2028+).
| # | Drug | Tier | Fit Score | Why |
|---|---|---|---|---|
| 1 | Elfabrio | 1 | 8.5 | Long diagnostic delay, high undiagnosed rate, high per-patient value, Chiesi desperate for share vs. Fabrazyme, Ada can surface Fabry symptoms |
| 2 | Lamzede | 2 | 7.0 | Ultra-high per-patient value ($117K fee!), zero competition, tiny patient pool |
| 3 | Filsuvez | 2 | 6.5 | Patient navigation opportunity (not diagnostic); EB diagnosed early |
| 4 | Seralutinib | 2 | 6.0 | Trial Finder; good PAH diagnostic delay story; PROSERA miss risk |
| 5 | Raxone | 3 | 5.5 | EU-only, niche |
| 6 | Arbor (ABO-101) | 3 | 5.0 | Too early; revisit at Phase 3 |
| 7 | Ferriprox | 3 | 4.0 | Generic competition, patients in care |
| 8 | Trimbow | NO | 2.0 | Wrong economics |
| 9 | Fostair | NO | 1.5 | Wrong economics, mature |
Lead with Elfabrio. Frame around Chiesi's challenge as a new Fabry ERT entrant fighting Sanofi's Fabrazyme monopoly with lost EU orphan exclusivity. Every undiagnosed Fabry patient Ada finds = $18K–$27K to Ada and $225K first-year revenue to Chiesi.
Bundle Lamzede as secondary. "We can also find patients for your monopoly ultra-orphan therapy — each patient found = $117K+ in Ada fees."
Key decision-maker: Giacomo Chiesi (EVP Global Rare Diseases, third-generation family member)
US contact: Jon Zwinski (SVP Region USA)